Erytech Pharma SA (NASDAQ:ERYP) Expected to Post Earnings of -$1.03 Per Share

Wall Street brokerages forecast that Erytech Pharma SA (NASDAQ:ERYP) will announce earnings of ($1.03) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Erytech Pharma’s earnings. The firm is scheduled to report its next quarterly earnings report before the market opens on Wednesday, September 18th.

According to Zacks, analysts expect that Erytech Pharma will report full-year earnings of ($3.40) per share for the current fiscal year, with EPS estimates ranging from ($3.58) to ($3.22). For the next year, analysts forecast that the company will report earnings of ($3.09) per share, with EPS estimates ranging from ($3.36) to ($2.82). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Erytech Pharma.

Several equities analysts recently issued reports on ERYP shares. JMP Securities reiterated a “market outperform” rating and issued a $13.00 price objective on shares of Erytech Pharma in a research report on Thursday, September 5th. Zacks Investment Research cut Erytech Pharma from a “hold” rating to a “sell” rating in a research note on Thursday. ValuEngine upgraded Erytech Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th. Finally, Cowen restated a “buy” rating on shares of Erytech Pharma in a research note on Wednesday.

Shares of ERYP remained flat at $$5.28 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.26 and a quick ratio of 7.19. The business’s 50 day simple moving average is $5.44 and its two-hundred day simple moving average is $6.90. Erytech Pharma has a 52 week low of $5.20 and a 52 week high of $10.65.

Erytech Pharma Company Profile

ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.

See Also: What is a support level?

Get a free copy of the Zacks research report on Erytech Pharma (ERYP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Erytech Pharma (NASDAQ:ERYP)

Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.